Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2010
06/17/2010WO2010048207A3 Aryl gpr120 receptor agonists and uses thereof
06/17/2010WO2010047737A3 Antimicrobial indoline compounds for treatment of bacterial infections
06/17/2010WO2010046869A3 Tetrahydronaphthalene compounds
06/17/2010WO2010044981A3 Benzoquinoline inhibitors of vesicular monoamine transporter 2
06/17/2010WO2010041141A3 Oil-based foamable carriers and formulations
06/17/2010WO2010040188A9 Biodegradable polymer - bioactive moiety conjugates
06/17/2010WO2010039187A3 Fused diimidazodiazepine compounds and methods of use and manufacture thereof
06/17/2010WO2010033598A3 System and method for utilizing microbubbles and liposomes as viral sequestering agents
06/17/2010WO2010033444A8 Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
06/17/2010WO2010033392A3 Methods and kits for treating cluster headache disorders
06/17/2010WO2010033248A3 Neutral nanotransporters
06/17/2010WO2010032113A3 Composition and use of a long-acting oral bioadhesive endoparasiticide gel based on doramectin
06/17/2010WO2010031801A3 Composition and methods for modulating toll-like receptor activity
06/17/2010WO2010031184A8 Azaindole derivatives as crth2 receptor antagonists
06/17/2010WO2010031096A8 Antimicrobially and antivirally acting composition
06/17/2010WO2010031043A3 Reducing or preventing neuroinflammation or neurotoxicity
06/17/2010WO2010030735A3 Stabilized coating for pharmaceutical formulations
06/17/2010WO2010029575A3 Lyophilized docetaxel containing formulation
06/17/2010WO2010029104A3 Use of a pharmaceutical composition for the local treatment of infections, and medical product
06/17/2010WO2010028189A3 Compounds, compositions and methods of using same for modulating uric acid levels
06/17/2010WO2010028132A3 Novel choline cocrystal of epalrestat
06/17/2010WO2010028088A3 Sulfur-linked compounds for treating opthalmic diseases and disorders
06/17/2010WO2010028079A3 Synthetic methods and derivatives of triphosphate oligonucleotides
06/17/2010WO2010027458A3 Pdk inhibitor compounds and methods of use thereof
06/17/2010WO2010025931A3 Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2 -methyl-propyl) - phenol and an antiepileptic
06/17/2010WO2010025436A3 Nitrogen and sulfur-containing heterocycle derivatives
06/17/2010WO2010025295A3 Compounds that modulate intracellular calcium
06/17/2010WO2010025135A3 Trimeprazine and ethopropazine derivatives for promoting bone growth
06/17/2010WO2010022313A3 Processes for the preparation of sglt2 inhibitors
06/17/2010WO2010022055A3 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
06/17/2010WO2010022051A3 Disruptors of early/recycling endosomes
06/17/2010WO2010022043A3 Targeting of histone deacetylase 2 and protein kinase ck2 for treatment of inflammatory diseases
06/17/2010WO2010021473A3 Pharmaceutical formulation
06/17/2010WO2010017821A8 Coated tablets with a remaining degradation surface over the time
06/17/2010WO2010017436A3 Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
06/17/2010WO2010015260A3 Administration by infusion for the treatment of ischemic effects
06/17/2010WO2010013141A3 Substantially pure rosiglitazone hydrogen sulfate
06/17/2010WO2010007116A3 Pyridons as pdk1 inhibitors
06/17/2010WO2009154463A3 Butyrate as a medicament to improve visceral perception in humans
06/17/2010WO2009149318A3 Mirnas as therapeutic targets in cancer
06/17/2010WO2009140972A3 Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease
06/17/2010WO2009113703A3 Orally-disintegrating solid preparation
06/17/2010WO2009090661A9 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
06/17/2010WO2009060197A8 Imidazopyridazines for use as protein kinase inhibitors
06/17/2010WO2008128740A8 Titration of tapentadol
06/17/2010WO2008050199A3 Substituted phenylmethyl bicyclocarboxyamide compounds
06/17/2010US20100154072 siRNA Kinase and Methods of Use
06/17/2010US20100154071 Fxdy5 modulators for treating, diagnosing, and detecting cancer
06/17/2010US20100152704 Method for Intravesical Drug Delivery
06/17/2010US20100152449 8a,14-DIHYDROXY-7,8-DIHYDROCODEINONE
06/17/2010US20100152446 Piperidine Derivatives
06/17/2010US20100152442 4-anilino quinazoline derivatives as antiproliferative agents
06/17/2010US20100152414 Multi-arm polymer prodrugs
06/17/2010US20100152305 Methods of treatment of hyperuricemia and associated disease states
06/17/2010US20100152304 Pharmaceutical composition comprising periplaneta americana or its ethanol extract and a method of using the same for treating inflammations
06/17/2010US20100152303 Agents and method for increasing brain chaperonin levels
06/17/2010US20100152302 Novel crystalline forms of atovaquone
06/17/2010US20100152301 Treatment of Viral Infections
06/17/2010US20100152300 Stabilized compositions of alkylating agents and methods of using same
06/17/2010US20100152299 Process for making compositions with poorly compressible therapeutic compounds
06/17/2010US20100152298 Present invention relates to a treatment for the management of cancer more specially the use of Flutamide anti-androgen drugsa
06/17/2010US20100152297 Composition for regulating cellular senescence comprising n-[2-(cyclohexy-loxyl)-4-nitrophenyl]-methanesulfonamide
06/17/2010US20100152296 Photopolymerization material for gums isolation
06/17/2010US20100152295 Methods of reducing small, dense ldl particles
06/17/2010US20100152294 Assays For Detecting Inhibitors Of Binding Between COX-2 And PDZ Proteins
06/17/2010US20100152293 Use of polyunsaturated ketones for the treatment of psoriasis
06/17/2010US20100152291 Production method of capsinoid by dehydrating condensation, stabilizing method of capsinoid, and capsinoid composition
06/17/2010US20100152290 Benzo Lipoxin Analogues
06/17/2010US20100152288 NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF
06/17/2010US20100152286 Method for Producing Fucoxanthin
06/17/2010US20100152285 Flavononol Renin Inhibitor Compounds and Methods of Use Thereof
06/17/2010US20100152284 Prevention and reversal of chemotherapy-induced peripheral neuropathy
06/17/2010US20100152283 Tetrahydrocannabinol modulators of cannabinoid receptors
06/17/2010US20100152282 Use of double stranded rna hairpin duplexes in gene silencing
06/17/2010US20100152281 Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
06/17/2010US20100152280 Modulation of sid-1 expression
06/17/2010US20100152279 RNAi Inhibition of Serum Amyloid A For Treatment of Glaucoma
06/17/2010US20100152278 RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
06/17/2010US20100152277 Diacylglycerol acyltransferase assay
06/17/2010US20100152276 Deuterated aminocyclohexyl ether compounds and processes for preparing same
06/17/2010US20100152275 Drug or Supplement Combination with Conjugated Linoleic Acid for Fat Loss in Mammals
06/17/2010US20100152274 Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester
06/17/2010US20100152273 Low-viscous anthracycline formulation
06/17/2010US20100152272 Functionalized drugs and polymers therefrom
06/17/2010US20100152271 Estrogen receptor modulators and uses thereof
06/17/2010US20100152269 Modified-release formulations of azabicyclo derivatives
06/17/2010US20100152268 Stable atorvastatin formulations
06/17/2010US20100152267 Novel rifamycin 3,4-(3-substituted aminomethyl) fused pyrrolo derivatives
06/17/2010US20100152265 Indazole derivatives
06/17/2010US20100152264 3- to 7-membered 1,3-diaza-4-oxo-heterocyclic derivatives capable of releasing active aldehydes or ketones
06/17/2010US20100152263 Therapy for the treatment of disease
06/17/2010US20100152262 Buccal, polar and non-polar spray containing ondansetron
06/17/2010US20100152261 Novel nitrogen-containing heterocyclic compound
06/17/2010US20100152260 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
06/17/2010US20100152259 Angiotensin ii receptor antagonists
06/17/2010US20100152258 Angiotensin ii receptor antagonists
06/17/2010US20100152257 Antagonists of lysophosphatidic acid receptors
06/17/2010US20100152256 inhibitors of the chemotaxis of chemokine ligand 1(CXCL1) induced neutrophils, polymorphonucleate and mononucleate cells, such as (2R)-2-{4-[(isopropylsulfonyl)amino]phenyl}propanamide, used for the treatment of respiratory system disorders, angiogenesis and melanoma
06/17/2010US20100152255 Organic Compounds
06/17/2010US20100152254 Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof
1 ... 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 ... 7860